$111 Million is the total value of Lynx1 Capital Management LP's 12 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
BLU | Sell | BELLUS HEALTH INC NEW | $25,155,000 | -3.9% | 2,382,127 | -15.9% | 22.69% | +1.8% |
MRUS | Sell | MERUS N V | $12,280,000 | -45.8% | 613,071 | -38.8% | 11.08% | -42.6% |
CBAY | Sell | CYMABAY THERAPEUTICS INC | $8,140,000 | +6.5% | 2,325,833 | -10.2% | 7.34% | +12.8% |
IMUX | Sell | IMMUNIC INC | $3,388,000 | -11.6% | 1,072,288 | -2.9% | 3.06% | -6.4% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
MERUS N V | 8 | Q3 2023 | 21.9% |
ALPINE IMMUNE SCIENCES INC | 8 | Q3 2023 | 20.2% |
CYMABAY THERAPEUTICS INC | 8 | Q3 2023 | 10.0% |
THESEUS PHARMACEUTICALS INC | 8 | Q3 2023 | 5.6% |
PIERIS PHARMACEUTICALS INC | 8 | Q3 2023 | 5.8% |
KINNATE BIOPHARMA INC | 7 | Q3 2023 | 18.0% |
PARDES BIOSCIENCES INC | 7 | Q2 2023 | 11.0% |
PASSAGE BIO INC | 7 | Q3 2023 | 4.0% |
BELLUS HEALTH INC NEW | 6 | Q1 2023 | 22.7% |
CABALETTA BIO INC | 4 | Q3 2023 | 22.6% |
View Lynx1 Capital Management LP's complete holdings history.
Latest filings
Type | Filed |
---|---|
4 | 2024-04-23 |
SC 13G | 2024-04-01 |
SC 13G | 2024-03-29 |
SC 13G | 2024-02-16 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View Lynx1 Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.